CenterBook Partners LP Grows Holdings in BioNTech SE Sponsored ADR $BNTX

CenterBook Partners LP grew its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 27.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 236,175 shares of the company’s stock after acquiring an additional 50,684 shares during the period. BioNTech accounts for 1.1% of CenterBook Partners LP’s portfolio, making the stock its 14th biggest position. CenterBook Partners LP’s holdings in BioNTech were worth $22,484,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Larson Financial Group LLC boosted its stake in shares of BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after buying an additional 127 shares during the last quarter. Mackenzie Financial Corp boosted its stake in shares of BioNTech by 4.0% during the 3rd quarter. Mackenzie Financial Corp now owns 4,290 shares of the company’s stock valued at $418,000 after buying an additional 165 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in BioNTech by 1.0% during the second quarter. Ameriprise Financial Inc. now owns 28,815 shares of the company’s stock worth $3,068,000 after purchasing an additional 289 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after purchasing an additional 305 shares during the last quarter. Finally, Probity Advisors Inc. lifted its stake in BioNTech by 14.2% during the fourth quarter. Probity Advisors Inc. now owns 2,863 shares of the company’s stock worth $273,000 after purchasing an additional 357 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Stock Performance

BNTX stock opened at $88.08 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.74 and a current ratio of 8.80. The stock has a market capitalization of $22.27 billion, a price-to-earnings ratio of -14.98 and a beta of 1.33. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The stock’s fifty day moving average is $94.54 and its two-hundred day moving average is $98.87.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. The company had revenue of $1.06 billion during the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. On average, research analysts predict that BioNTech SE Sponsored ADR will post -4.66 EPS for the current year.

BioNTech announced that its board has initiated a share repurchase plan on Thursday, May 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 4.2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

BNTX has been the topic of several research analyst reports. Truist Financial upgraded BioNTech to a “strong-buy” rating in a research note on Wednesday, March 25th. Canaccord Genuity Group reduced their price objective on BioNTech from $171.00 to $158.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Bank of America restated a “buy” rating and set a $128.00 price objective on shares of BioNTech in a research note on Tuesday, March 10th. The Goldman Sachs Group restated a “buy” rating on shares of BioNTech in a research note on Wednesday, March 11th. Finally, Wells Fargo & Company reduced their price objective on BioNTech from $150.00 to $140.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and an average target price of $129.56.

Insider Transactions at BioNTech

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the sale, the chief operating officer directly owned 399,387 shares in the company, valued at approximately $44,156,226.72. This trade represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.20% of the company’s stock.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.